Literature DB >> 23893731

The yeast product Milmed enhances the effect of physical exercise on motor performance and dopamine neurochemistry recovery in MPTP-lesioned mice.

Trevor Archer1, Anders Fredriksson.   

Abstract

Both clinical and laboratory studies have demonstrated that different types of physical exercise may alleviate Parkinsonism yet evidence for complete restoration of motor function and biomarker integrity are difficult to identify. MPTP (1 × 30 mg/kg, s.c., 4 groups) or saline (vehicle 1 × 5 ml/kg, s.c., 1 group) were administered in a single dose regime over three consecutive weeks on Fridays. Three MPTP groups were given four 30-min periods/week (Mondays to Thursdays), of these two groups, MPTP + Exer + M(i) and MPTP + Exer + M(ii); the former were introduced to exercise and Milmed (oral injection) on the week following the 1st MPTP injection and the latter on the Monday prior to the 1st injection of MPTP onwards. One MPTP group, MPTP + Exer, was given access to exercise (running wheels) from the week following the 1st MPTP injection onwards. The fourth MPTP group, MPTP-NoEx, and the Vehicle group were only given access to exercise on a single day each week (Wednesdays, exercise test) from the week following the 1st MPTP injection onwards. The exercise/exercise + Milmed regime was maintained for a further 9 weeks. It was observed that exercise by itself ameliorated MPTP-induced deficits regarding motor function and dopamine loss only partially whereas in the groups combining exercise with twice weekly dosages of Milmed the MPTP-induced deficits were abolished by the 10th week of the intervention. The three main conclusions that were drawn from correlational analyses of individual mice were: (i) that DA integrity was observed to be a direct function of ability to express running exercise in a treadmill wheel-running arrangement, and (ii) that DA integrity was observed to be a direct function of the capacity for motor performance as measured by spontaneous motor activity and subthreshold L-Dopa (5 mg/kg) induced activity in the motor activity test chambers, and (iii) that the extent to which running exercise in a running wheel was predictive of later motor performance in the activity test chambers was highly convincing.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23893731     DOI: 10.1007/s12640-013-9405-4

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  58 in total

1.  MPTP-induced hypoactivity in mice: reversal by L-dopa.

Authors:  A Fredriksson; A Plaznik; E Sundström; G Jonsson; T Archer
Journal:  Pharmacol Toxicol       Date:  1990-10

Review 2.  Prospects of yeast systems biology for human health: integrating lipid, protein and energy metabolism.

Authors:  Dina Petranovic; Keith Tyo; Goutham N Vemuri; Jens Nielsen
Journal:  FEMS Yeast Res       Date:  2010-10-26       Impact factor: 2.796

3.  Enhancing neuroplasticity in the basal ganglia: the role of exercise in Parkinson's disease.

Authors:  Giselle M Petzinger; Beth E Fisher; Jon-Eric Van Leeuwen; Marta Vukovic; Garnik Akopian; Charlie K Meshul; Daniel P Holschneider; Angelo Nacca; John P Walsh; Michael W Jakowec
Journal:  Mov Disord       Date:  2010       Impact factor: 10.338

4.  Neuroprotective effects and mechanisms of exercise in a chronic mouse model of Parkinson's disease with moderate neurodegeneration.

Authors:  Yuen-Sum Lau; Gaurav Patki; Kaberi Das-Panja; Wei-Dong Le; S Omar Ahmad
Journal:  Eur J Neurosci       Date:  2011-03-07       Impact factor: 3.386

5.  Electromechanical effects on multilayered cells in nonuniform rotating fields.

Authors:  José Luis Sebastián; Sagrario Muñoz; Miguel Sancho; Genoveva Martínez; Gabriel Alvarez
Journal:  Phys Rev E Stat Nonlin Soft Matter Phys       Date:  2011-07-28

6.  Monoamine oxidase A activity and norepinephrine level in hippocampus determine hyperwheel running in SPORTS rats.

Authors:  Masaki Morishima; Nagakatsu Harada; Sayuri Hara; Atsuko Sano; Hiromasa Seno; Akira Takahashi; Yusuke Morita; Yutaka Nakaya
Journal:  Neuropsychopharmacology       Date:  2006-01-18       Impact factor: 7.853

7.  Exercise therapy for Parkinson's disease.

Authors:  S S Palmer; J A Mortimer; D D Webster; R Bistevins; G L Dickinson
Journal:  Arch Phys Med Rehabil       Date:  1986-10       Impact factor: 3.966

Review 8.  Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse.

Authors:  R E Heikkila; B A Sieber; L Manzino; P K Sonsalla
Journal:  Mol Chem Neuropathol       Date:  1989-06

9.  The novel anticonvulsant lamotrigine prevents dopamine depletion in C57 black mice in the MPTP animal model of Parkinson's disease.

Authors:  S A Jones-Humble; P F Morgan; B R Cooper
Journal:  Life Sci       Date:  1994       Impact factor: 5.037

10.  (S)-UH-301 antagonizes (R)-8-OH-DPAT-induced cardiovascular effects in the rat.

Authors:  L Björk; S Lindgren; U Hacksell; T Lewander
Journal:  Eur J Pharmacol       Date:  1991-07-09       Impact factor: 4.432

View more
  4 in total

1.  Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-01-29       Impact factor: 3.911

Review 2.  Impact of Plant-Derived Flavonoids on Neurodegenerative Diseases.

Authors:  Silvia Lima Costa; Victor Diogenes Amaral Silva; Cleide Dos Santos Souza; Cleonice Creusa Santos; Irmgard Paris; Patricia Muñoz; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2016-03-07       Impact factor: 3.911

3.  Restoration of MPTP-induced deficits by exercise and Milmed(®) co-treatment.

Authors:  Trevor Archer; Danilo Garcia; Anders Fredriksson
Journal:  PeerJ       Date:  2014-08-26       Impact factor: 2.984

4.  Effect of treadmill exercise on catalepsy and the expression of the BDNF gene in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine -induced Parkinson in male NMRI mice.

Authors:  Neda Nikokalam Nazif; Maryam Khosravi; Ramesh Ahmadi; Maryam Bananej; Ahmad Majd
Journal:  Iran J Basic Med Sci       Date:  2020-04       Impact factor: 2.699

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.